COMMUNIQUÉS West-GlobeNewswire

ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
26/04/2019
Zynquista TM now approved in the European Union for treatment of adults with type 1 diabetes PARIS and THE WOODLANDS, TX - April 26, 2019 - The European Commission has granted marketing authorization for Zynquista (TM [...]
ZynquistaTM désormais approuvé dans l'Union européenne pour le traitement du diabète de type 1 de l'adulte
26/04/2019
Zynquista TM désormais approuvé dans l'Union européenne pour le traitement du diabète de type 1 de l'adulte Paris et The Woodlands (Texas) - Le 26 avril 2019 - La Commission européenne a délivré une autorisation de mise [...]
Zynquista™ now Approved in the European Union for Treatment of Adults With Type 1 Diabetes
26/04/2019
PARIS and THE WOODLANDS, Texas, April 26, 2019 (GLOBE NEWSWIRE) -- The European Commission has granted marketing authorization for Zynquista™ (sotagliflozin)*, developed by Sanofi and Lexicon (Nasdaq: LXRX). Zynquista [...]
Avricore Health Provides Corporate Update
26/04/2019
Vancouver, April 26, 2019 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR) (“Avricore”) announced today the resignation of Ms. Leanne Ratzlaff as Corporate Secretary effective immediately. Due to the growth in [...]
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26/04/2019
CHICAGO, April 26, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable [...]
CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019
26/04/2019
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based [...]
Genkyotex : mise à disposition du document de référence 2018
26/04/2019
ARCHAMPS, France, 26 avr. 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris et Euronext Brussels : FR0013399474 – GKTX), la société biopharmaceutique leader des thérapies NOX, annonce aujourd’hui que son document de [...]
Innovate Biopharmaceuticals First Quarter 2019 Financial Results and Operational Progress Updates - Webcast Details
26/04/2019
RALEIGH, N.C., April 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation [...]
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
26/04/2019
CHMP issues positive opinion for Libtayo ® (cemiplimab) in advanced cutaneous squamous cell carcinoma Currently no approved treatments in the European Union for advanced cutaneous squamous cell carcinoma (CSCC) CSCC is [...]
Le CHMP délivre un avis favorable pour Libtayo® (cemiplimab) dans le traitement du carcinome épidermoïde cutané au stade avancé
26/04/2019
Le CHMP délivre un avis favorable pour Libtayo ® (cemiplimab) dans le traitement du carcinome épidermoïde cutané au stade avancé Aucun médicament indiqué dans le traitement du carcinome épidermoïde cutané (CEC) n'est [...]
Marche de sensibilisation à l’autisme
26/04/2019
MONTRÉAL, 26 avr. 2019 (GLOBE NEWSWIRE) -- Samedi le 27 avril 2019, prendra place la marche pour l’autisme qui clôture le mois de sensibilisation à l’autisme au Québec. Cette année, Autisme Montréal a mis sur pied une [...]
Precipio Takes Final Step towards Regaining Nasdaq Compliance
26/04/2019
Company announces 1-for-15 reverse stock split NEW HAVEN, Conn., April 26, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) today announced that it has implemented a 1-for-15 [...]
Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct® (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A
26/04/2019
Bagsværd, Denmark, 26 April 2019 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), adopted a positive opinion for the use of [...]
Emisphere Development Update
26/04/2019
ROSELAND, N.J., April 26, 2019 (GLOBE NEWSWIRE) -- Novo Nordisk today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like [...]
Key Patent Coverage for Asklepion Pharmaceuticals’ Investigational Candidate Extended to 2036
26/04/2019
BALTIMORE, April 26, 2019 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of novel therapeutics for rare pediatric diseases, today [...]
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors
26/04/2019
– Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalized with Life-Threatening Bleeding – – Initial Launch in Select Countries to Begin 2H 2019 – SOUTH SAN FRANCISCO, Calif., April 26, 2019 [...]
CB2 Insights to Host FY2018 Earnings Call on May 1, 2019
26/04/2019
TORONTO, April 26, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (“CB2” or the “Company”) (CSE:CBII), a leading provider of medical cannabis-focused Real World Evidence to the healthcare sector, will be hosting its fiscal year [...]
Aequus Announces Filing of Prospectus Supplement and an Update to Previously Announced Public Offering of Convertible Debenture Units
26/04/2019
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, April 26, 2019 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (the “ Company ”) (TSX-V: [...]
Nexstim Plc: Managers' Transactions
26/04/2019
Company announcement, Helsinki, 26 April 2019 at 4pm (EET) Nexstim Plc: Managers' Transactions Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( "Nexstim" or "Company" ), the targeted neuromodulation company developing and marketing [...]

Pages